Physician profile
Sonal Kumar
NPI 1952523268
$1,000,800.09
in general payments reported to CMS, 2019-2025
26 companies · $368K in 2025
The $368K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $20K · 2021: $40K · 2022: $52K · 2023: $176K · 2024: $304K · 2025: $368K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $353K · Consulting Fee: $292K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $95K · Travel and Lodging: $78K · Food and Beverage: $20K · Honoraria: $11K · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $352,773.84 |
| Consulting Fee | $292,494.08 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $94,550.00 |
| Travel and Lodging | $77,703.90 |
| Food and Beverage | $19,644.03 |
| Honoraria | $10,583.00 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $233,910.89 | 2021-2025 | Wegovy, Ozempic |
| Intercept Pharmaceuticals, INC. | $209,961.23 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $208,551.66 | 2023-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $164,594.55 | 2019-2025 | Livdelzi, Epclusa |
| Madrigal Pharmaceuticals | $78,887.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59,990.47 | 2024-2025 | |
| Glaxosmithkline, LLC. | $17,625.61 | 2024-2025 | |
| Abbvie INC. | $12,459.91 | 2019-2024 | |
| Novo Nordisk As | $8,290.34 | 2025 | |
| Merck Sharp & Dohme LLC | $4,650.00 | 2019-2025 | |
| Boston Scientific Corporation | $515.70 | 2022-2024 | Resolution 360 Clip |
| Mallinckrodt Hospital Products INC. | $301.38 | 2022-2024 | Terlivaz |
| Alnylam Pharmaceuticals INC. | $269.10 | 2020-2025 | Givlaari, Oxlumo |
| Mirum Pharmaceuticals, INC. | $205.18 | 2025 | Livmarli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.93 | 2022-2025 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $129.49 | 2025 | Esophyx |
| Takeda Pharmaceuticals U.S.A., INC. | $116.63 | 2023-2025 | Entyvio |
| Aimmune Therapeutics, INC. | $79.13 | 2025 | Vowst |
| Dova Pharmaceuticals | $49.25 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $37.37 | 2025 | Envarsus |
| Lilly USA, LLC | $18.25 | 2025 | Mounjaro, Zepbound |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonal Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.